Volume | 60,602 |
|
|||||
News | - | ||||||
Day High | 36.02 | Low High |
|||||
Day Low | 35.33 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
35.83 | 35.33 | 36.02 | 35.94 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,372 | 60,602 | $ 35.64 | $ 2,159,912 | - | 20.83 - 40.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:03:04 | 2 | $ 35.39 | USD |
Collegium Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.13B | 31.96M | - | 566.77M | 48.16M | 1.51 | 23.51 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Collegium Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 35.47 | 36.5054 | 34.24 | 35.31 | 385,326 | -0.06 | -0.17% |
1 Month | 40.10 | 40.95 | 34.24 | 37.35 | 363,725 | -4.69 | -11.70% |
3 Months | 33.58 | 40.95 | 31.34 | 36.71 | 429,871 | 1.83 | 5.45% |
6 Months | 21.35 | 40.95 | 20.95 | 32.44 | 418,476 | 14.06 | 65.85% |
1 Year | 22.98 | 40.95 | 20.83 | 28.30 | 362,741 | 12.43 | 54.09% |
3 Years | 23.36 | 40.95 | 14.04 | 23.65 | 334,332 | 12.05 | 51.58% |
5 Years | 14.74 | 40.95 | 10.01 | 21.62 | 369,691 | 20.67 | 140.23% |
Collegium Pharmaceutical Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |